v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:            
Net loss $ (1,172,000) $ (1,808,000)   $ (5,162,000) [1] $ (9,559,000) [1] $ (14,121,000) [1]
Adjustments to reconcile net loss to net cash provided by operating activities:            
Depreciation and amortization       106,000  
Amortization of operating lease right-of-use asset       329,000  
Stock-based compensation expense 3,000 8,000   25,000 511,000  
Loss on disposals       2,618,000  
Fair value adjustment of warrants (66,000)   (67,000) 67,000  
Changes in operating assets and liabilities:            
Accounts receivable (16,000)   928,000  
Prepaid expenses and other current assets (424,000) 82,000   358,000 343,000  
Other long-term assets 13,000   13,000 163,000  
Accounts payable 379,000 (152,000)   (537,000) (1,106,000)  
Accrued expenses 147,000 126,000   (63,000) (438,000)  
Operating lease liability       (333,000)  
Deferred revenue       (4,345,000)  
Net cash provided by operating activities (1,067,000) (1,813,000)   (5,433,000) (10,716,000)  
Cash flows from investing activities:            
Purchases of property and equipment       (398,000)  
Net cash provided by investing activities       (398,000)  
Cash flows from financing activities:            
Proceeds from sale of Series B Convertible Preferred Stock 1,000,000        
Net cash provided by financing activities 1,000,000        
Net increase in cash and cash equivalents: (67,000) (1,813,000)   (5,433,000) (11,114,000)  
Cash and cash equivalents at beginning of period 4,098,000 9,531,000   9,531,000 20,645,000  
Cash and cash equivalents at end of period 4,031,000 7,718,000 $ 9,531,000 4,098,000 9,531,000 $ 20,645,000
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:            
Cash and cash equivalents 3,324,000 7,708,000 9,521,000 4,088,000 9,521,000  
Restricted cash 700,000      
Long-term restricted cash 7,000 10,000 10,000 10,000 10,000  
Supplemental disclosures of non-cash financing information:            
Reduction of operating lease right-of-use asset and lease liability upon lease modification       8,423,000  
Preferred stock issuance costs not yet paid 50,000        
Eos SENOLYTIXS Inc [Member]            
Cash flows from operating activities:            
Net loss (582,432) (78,761) (76,895) (253,020)    
Adjustments to reconcile net loss to net cash provided by operating activities:            
Parent-paid expenses treated as capital contribution 325,126 78,675 76,885 234,675    
Stock-based compensation expense 7,455 86 10 345    
Changes in operating assets and liabilities:            
Deferred assets (414,442)        
Prepaid expenses (75,000)        
Accrued expenses 654,227 18,000    
Net cash provided by operating activities (85,066)    
Cash flows from investing activities:            
Net cash provided by investing activities    
Cash flows from financing activities:            
Proceeds from short-term borrowings 100,000        
Net cash provided by financing activities 100,000    
Net increase in cash and cash equivalents:        
Cash and cash equivalents at beginning of period    
Cash and cash equivalents at end of period 14,934  
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:            
Cash and cash equivalents 14,934    
Supplemental disclosure of operating activities            
Interest paid    
Income taxes paid    
[1] The dollar amounts reported represent the amount of net loss, in thousands, reflected in Pulmatrix’s consolidated audited financial statements for each applicable year.